NCT06724042View on ClinicalTrials.gov

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

December 30, 2025

Primary Completion Date

December 30, 2028

Study Completion Date

December 30, 2029

Conditions
Advanced Solid TumorMetastatic Solid TumorAdvanced and/or Metastatic Solid Tumors
Interventions
DRUG

ISM5939

ISM5939 tablets will be administered orally once daily (QD).

DRUG

Cisplatin

Cisplatin will be administered intravenously in combination with ISM5939 on day 1 during each cycle.

DRUG

Docetaxel

Docetaxel will be administered intravenously in combination with ISM5939 on day 1 during each cycle.

DRUG

Pembrolizumab

Pembrolizumab will be administered intravenously in combination with ISM5939 on day 1 during each cycle.

All Listed Sponsors
lead

InSilico Medicine Hong Kong Limited

INDUSTRY